Jake is a Partner based in our San Francisco Bay Area office, focusing on later-stage private and public biotech investment opportunities. Jake has more than 25 years of experience in the life science industry as an investor, board director, research analyst and investment banker. He joins SR One from New Enterprise Associates (NEA), where he was an investing partner from 2006 to 2019 and was most recently a venture advisor. Jake founded NEA’s public healthcare investing practice in 2006, enabling the firm to invest in publicly traded biotechnology companies with venture-like return profiles.
He helped lead NEA to become one of the most active anchor investors in small-cap biotechnology investing over the last decade, investing over $600m in more than forty companies. Prior to NEA, Jake was a partner at MPM Capital with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons.
Jake has served on more than a dozen life sciences company boards, including Addex Therapeutics, Regulus Therapeutics, and Zenas Biopharma (all current), as well as Dermira (acquired by Eli Lilly) and Hyperion Therapeutics (acquired by Horizon Pharma).
Jake received his MBA from the Stanford Graduate School of Business and his BA in Economics from Dartmouth College. He holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and completed the Stanford GSB Directors’ Consortium executive education program.